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Objective. To identify by means of genetic analyses
individuals who are at risk of developing medullary thyroid
cancer that is a component of multiple endocrine
neoplasia.
Subjects. A three-generation kindred with clinically and
biochemically diagnosed medUllary thyroid cancer.
Method. Identification of a heterozygote mutation by
nucleic acid sequencing and restriction analyses.
Results. A heterozygote T -t C (Cys -t Arg) mutation at
codon 618 in exon 10 of the RET proto-oncogene was
identified in 4 family members who had previously been
diagnosed with medullary thyroid cancer. The same
mutation was also found in one of the proband's pre-
symptomatic children who subsequently underwent a pre-
emptive thyroidectomy. The genetic diagnosis was
confirmed by histology. No mutations were detected in any
other family members.
Conclusion. Identification of heterozygote germline
mutations in multiple endocrine neoplasia is direct, highly
accurate and cost-effective. This study demonstrates that,
appropriately used, molecular diagnosis can supersede
conventional biochemical methods in the management of
patients with inherited cancers.
S Atr Med J 1997; 87: 39-42.
Medullary thyroid cancer (MTC) accounts for about 10% of
all thyroid tumours. It occurs mainly as a sporadic disease
but at least 25% of cases appear to be familial. The familial
form of W.TC occasionally manifests in isolation but usually
occurs as a component of either multiple endocrine
neoplasia (MEN) type 2A, comprising MTC,
phaeochromocytoma and hyperparathyroidism, or the rarer
MEN type 28 characterised by MTC, phaeochromocytoma,
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mucosal neuromas and a marfanoid habitus. The syndromes
of MEN 2, including isolated familial medullary thyroid
cancer (FMTC), are inherited as autosomal dominant traits
which are thought to be fully penetrant.' Early diagnosis of
affected family members has important implications for
clinical management since it allows pre-emptive
thyroidectomy that is generally curative. Calcitonin
deficiency has no important consequences while
replacement of thyroxine is relatively easy.
Until recently, screening for the disease comprised
measurement of the calcitonin response to C-cell
secretagogues such as pentagastrin or calcium. Although
still in use, biochemical analysis has disadvantages such as
frequent false-positives, ambiguous results, unpleasant side-
effects and the fact that ongoing annual testing is necessary.
In 1987, mapping of the MTC gene to the centromeric
region of chromosome 10 opened up a new approach to the
identification of gene carriers by linkage analysis.,,3 While
useful, linkage analysis is, however, only 90 - 95% accurate
and to be informative requires the availability of multiple
family members.4 ln 1993 the RET proto-oncogene was
identified as the gene responsible for MEN 2 and FMTC. In
MEN 2A, a total of 19 different mutations in this gene has
now been detected in the germline of affected families."·
Virtually all of these are missense point mutations at any 1 of
5 cysteine residues (codons 609, 611, 618, 620 and 634) in
exons 10 or 11.7,8 By contrast, in patients with MEN 2B
germline mutations occur almost exclusively at codon 918 in
exon 16.5
Mutations in the RET proto-oncogene are implicated in
over 95% of families with MEN 2.. Several studies have also
demonstrated that all members within a kindred consistently
inherit the same RET mutation and that mutations have not
been identified in any family members who did not ultimately
manifest the disease or in any unrelated members.'o Failure
to identify a specific mutation has been reported in less than
5% of families with MEN 2.-,8 Therefore the almost invariable
occurrence of a limited number of mutations within discrete
regions of the RET proto-oncogene has made direct genetic
screening for MEN 2 and FMTC a feasible proposition. The
initial step is the identification of the exact mutation in the
proband or another affected family member. Thereafter all
members of the family at risk for the disease can be tested
by definitive genetic analysis and, if appropriate, the
necessary treatment can be initiated.
In this study we report on 17 members of a South African
kindred with clinically and biochemically diagnosed MTC
who were assessed by direct DNA analysis.
Subjects and methods
Patients
The proband was a 30-year-old woman who presented in
1993 with a thyroid tumour and an elevated calcitonin
response to pentagastrin provocation. Histology confirmed a
medullary thyroid carcinoma. Questioning revealed that an
uncle had died of a metastatic thyroid tumour and there was
similar anecdotal evidence about her paternal grandfather.
Subsequently other 'at risk' family members who were
agreeable were screened for MEN 2; this included the
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proband's father, her 5 children, 3 sisters and her cousin.
Initially screening was performed by the pentagastrin
stimulation test for MTC and by the measurement of urinary
catecholamines and serum calcium and phosphate
concentrations for phaeochromocytoma and
hyperparathyroidism, respectively.
Calcitonin stimulation test
The plasma calcitonin level was measured before and 2, 5,
10 and 15 minutes after intravenous administration of
pentagastrin (0.5 IJg/kg body weight in 2 ml normal saline)
given over a 15-second period." The test was considered
positive when there was'a 2 - 3-fold peak calcitonin increase
above the basal concentration or a peak calcitonin response
in excess of 200 ng/l.
Screen for phaeochromocytoma and
parathyroid disease
Phaeochromocytoma was screened for by the measurement
of urinary noradrenaline, adrenaline and dopamine levels
using reverse-phase chromatography with electrochemical
detection." This has been shown to be highly sensitive.'3
Serum calcium (corrected for albumin) and phosphate were
used to screen for the presence of hyperparathyroidism. In
the absence of abnormal levels, parathyroid hormone level
was not determined.
DNA analysis
The details of the procedure are given in the Appendix at the
end of the article. In essence, genomic DNA was obtained
from 17 family members, and exons 10 and 11 of the RET
proto-oncogene were amplified by the polymerase chain
reaction (PCR). The amplified segments were sequenced in
both directions with the ABI Prism 310 Automated Genetic
Analyzer. The sequence results were confirmed with a
specific restriction endonuclease (Cfo I) to distinguish
between the mutated and wild-type (normal) genes. Initially
the mutation was sought in the index case of the kindred
and compared with an unrelated reference subject.




An abnormal calcitonin response to pentagastrin was
observed in the proband's father, a sister and a cousin
(Fig. 1: 1-2, 11-3 and 11-1, respectively), all of whom
immediately underwent thyroidectomies on the basis of
these results. Medullary thyroid carcinomas were confirmed
histologically in each of these individuals. All other family
members on whom the test was performed screened
negative at that time. Pentagastrin stimulation tests were
continued annually, however. Within 3 years an exaggerated
calcitonin response was detected in the proband's 11-year-
old asymptomatic daughter and a 3-year-old son
demonstrated an ambiguous elevated basal level.
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Fig. 1. Confirmation of RET proto-oncogene codon 618 (Cys --+
Arg) mutation by the presence of a heterozygote Cfo 1restriction
site (seen as 183 bp, 120 bp and 63 bp) in the proband (11-2) and
her father (1-2), sister (11-3), cousin (11-1) and daughter (11I-2) and
(fil!I= died of unknown thyroid disease; .. = died of medullary
thyroid cancer; .ore = RET codon 618 mutation; DorO= RET
codon 618 mutation absent; CON = control).
calcitonin response to pentagastrin. This high degree of
mutation specificity within a kindred is a valuable tool as it
permits presymptomatic, definitive diagnostic genetic testing
on other members of the family who may be at risk.,o,14 In
some instances, particularly in children, such tests can allow
presymptomatic diagnosis which has life-protecting
potential.
In this kindred screening positively identified the
proband's 11-year-old daughter as a carrier of the mutation
and therefore at risk of developing MTC. This child was
clinically asymptomatic, although she had recently
manifested an elevated calcitonin response to pentagastrin
provocation, The positive identification of the MTC-
associated mutation provided unequivocal support for the
diagnosis and allowed pre-emptive thyroidectomy without
delay. Histological examination of the resected thyroid
revealed hyperplasia of the C-cells of the medulla and a
small medullary carcinoma. Earlier genetic analysis of this
child, had it been available, would have allowed surgery
prior to the development of potentially life-threatening
changes in the thyroid. In the case of the proband's 3-year-
old son, a recent pentagastrin stimulation test was
ambiguous in that there was no apparent calcitonin
response but the basal level was elevated 2-fold above
normal. The absence of the mutation in this child served to
eliminate ongoing anxiety and the possibility of an
inappropriate thyroidectomy. The 8 remaining family
members who were at risk because of a parent with the
defective gene were all found to have the normal nucleic
acid sequence for codon 618. These individuals can now be
considered to carry only the normal risk of developing a
tumour of the medullary thyroid and require no further
special monitoring for the disease.'o",
The absence of phaeochromocytoma and
hyperparathyroidism on clinical and laboratory investigation
at initial presentation of this family suggested a diagnosis of
FMTC, in accordance with the criteria set down by the
International RET Mutation Consortium which specified at
least 4 confirmed cases of MTC and no
phaeochromocytoma or parathyroid disease in patients or
living relatives. The isolated familial form of MTC appears to
be rare, having been reported in only 23 of 361 (6.4%)
families Vlorldwide; mutations at codons 618, as seen in this
study, are the most frequent." Recently, more than 3 years
after diagnosis, the proband's father presented with a
phaeochromocytoma. The diagnosis in this family was
consequently revised to that of MEN 2A, supporting a
suggestion 15 that the entity of true isol2ted FMTC may not
exist. All patients with a germline mutation of the RET proto-
oncogene should therefore be monitored regularly for both
phaeochromocytoma and hyperparathyroidism.
As shown in this study and by others'&-l. there are several
important advantages to the use of genetic analysis in the
diagnosis of MEN 2 and the familial forms of MTC. Firstly,
because penetrance is 100% a genetic diagnosis allows
early thyroidectomy to be undertaken, before the age of
5 - 6 years, avoiding the need for repeated biochemical
testing in genetically normal individuals. Besides the
improved clinical outcome and the greater sense of security,
the elimination of unnecessary screening is extremely cost-
effective in the long run. Genetic testing requires only a
60Ij'-- .... Wlllii ....... __ '--....,..",....., __ ..... -......,--~'--' ~- - ._ 1 1
Indirect mutation analysis
The heterozygote Cfo I restriction site created by the CYS61.
-> Arg (TGC -> CGC) transition was observed as 3 bands
(183 bp, 120 bp and 63 bp) on electrophoresis in all 5
individuals in whom the heterozygote point mutation was
found by sequencing (Fig. 1). This finding reaffirmed the
presence of the mutation.
Direct nucleic acid sequencing revealed a T -> C (Cys ->
Arg) transition at codon 618 in exon 10 of the RET proto-
oncogene in the kindred studied. The association between
this specific mutation and MTC in this family was clearly
evident in the presence of the same mutation in all 4
members with histologically confirmed MTC who had
previously had thyroidectomies on the basis of an elevated
Direct mutation analysis
PCR amplification of exons 10 and 11 resulted in products
of 183 and 219 bp, respectively. Single-strand nucleic acid
sequencing did not reveal any mutation in exon 11. In exon
10, however, a heterozygote T -> C (Cys -> Arg) transition at
codon 618 was detected in the proband. The same mutation
was sUbsequently detected in the proband's father, sister
and cousin as well as her pre-symptomatic daughter.
Confirmation of this mutation was obtained by sequencing
of the complementary DNA strand. The mutation was not
found in the unrelated control or in any of the 12 remaining
members of the kindred, including the 3-year-old child with
ambiguous calcitonin levels on pentagastrin testing in whom
thyroidectomy was being considered.
Catecholamines and calcium levels
None of the family members diagnosed with MTC had
elevated urinary catecholamine or serum calcium and
phosphate concentrations at the time of the original
diagnosis. After 3.5 years the proband's father was found to
have a raised adrenaline level and was subsequently
diagnosed with a phaeochromocytoma.
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single blood sample on one occasion. Given the clinical
implications of the results, every precaution needs to be
taken to eliminate the possibility of error during the pre-
analytical, analytical and reporting stages of the analysis.
Some laboratories go so far as to recommend resampling
and repeat analysis of each pedigree prior to release of
results." With regard to technical aspects, all mutations
should be confirmed by sequencing of the reverse DNA
strand. In addition, wherever possible, restriction analysis
should be used to confirm the presence or absence of the
mutation.
This study, together with a recently published report on
MEN 2A in a black South African family,20 demonstrates the
clinical utility and cost-effectiveness of genetic screening in
selected monogenic, neoplastic disorders. Selected
laboratories in this country are now capable of doing this,
with a consequent substantial reduction in costs.
Biochemical screening of family members of a patient with
an apparent sporadic tumour may reveal affected
members!' It has been suggested that all patients with MTC
be tested for RET proto-oncogene mutations and, if positive,
other family members followed up.",22 This principle can be
more generally applied to other cancers in which sporadic
and familial cancers cannot be distinguished on clinical or
histological grounds.
Appendix
Genomic DNA was extracted by means of a salting out
procedure>" for amplification by PCR of exon 10 and part of
exon 11 of the RET proto-oncogene. Briefly, 1 IJg DNA was
amplified in a 50 IJI reaction containing 1 x reaction buffer
(pH 8.3), 1.5 mmol/l MgCI2, 200 IJmol/l dNTPs, 0.2 IJmol/l of
each primer and 1.25 U Taq polymerase. Genomic DNA was
denatured for 5 minutes at 95°C prior to 30 cycles through
95°C, 63°C, or 61 °c (for exon 10 or 11, respectively) and
noc for 30 seconds at each temperature followed by a
7-minute 72°C extension.
Sequences selected for the oligonucleotide primers were:
RET10F 5' GGA GGC TGA GTG GGC TAC GT 3'
RET10R 5' GAG GTG GTG GTG GTC CCG GC 3'
RET11 F 5' CCT CTG CGG TGC CM GCC TC 3'
RET11 R 5' AGC TGA CCG GGA AGG CCT GG 3'
obtained from Genbank by accession numbers U11521,
U11523, U11504 and MS 7464, respectively.
Direct bidirectional cycle sequencing of the PCR products
was performed with the Perkin Bmer Taq FS Dyedeoxy
Terminator Sequencing Kit followed by analysis on an
Applied Biosystems Prism 310 Automated Genetic Analyzer.
Heterozygote mutation analysis was carried out with the
Sequence Navigator Software (Applied Biosystems Version
1.0.1).
The presence of a heterozygote mutation in exon 10 was
verified by restriction digestion of the PCR product with the
endonuclease eto I. Restriction products were size-
separated by electrophoresis on a 12% polyacrylamide gel
and stained with ethidium bromide.
Research was funded by the University of Natal's Faculty of
Medicine (Kennedy-Potts Cancer Research Endowment).
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